在实验性肝硬化中对肝毒剂的代谢和药物动力学观点
Anuradha Mehra1, Roopal Mittal2, Amit Mittal1
1Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara (Punjab) 144411, India.
Current drug metabolism
|February 20, 2026
概括
本综述探讨了研究肝硬化,由痕引起的严重肝病的实验模型. 它评估了当前的动物模型,并强调了新兴的替代方案,如器官芯片系统,以更好地理解和治疗.
科学领域:
- 肝病学和毒理学 肝病学和毒理学
- 实验病理学实验病理学
- 药物发现 药物发现 药物发现
背景情况:
- 肝硬化是一种进展性肝脏疾病,其表现为原蛋白过度产生和痕,可能导致肝功能衰竭或癌症.
- 纤维化是肝硬化的前体,在早期可能是可逆的. 主要病因包括病毒性肝炎,酒精,NAFLD和药物诱导的肝损伤.
- 大约50%的肝损伤病例源于药物诱导的肝损伤,这强调了需要可靠的实验模型.
研究的目的:
- 为研究肝硬化提供用于诱导肝损伤的各种实验模型的深入审查.
- 在这些模型中,批判性地分析肝毒物质,氧化应激,线粒体病理和炎症的机制性理解.
- 突出新兴的替代模型并讨论肝纤维化和肝硬化的生物标志物,终点和治疗策略.
主要方法:
- 对体内,体外和操作性动物模型 (化学,药物,饮食,胆道绑定) 的现有文献的审查.
- 对肝毒性,氧化应激,线粒体功能障碍和炎症的机制性见解的分析.
- 评估新的方法,如器官芯片系统,3D共同培养和生物工程组织.
主要成果:
- 传统的动物模型提供了洞察力,但在翻译相关性方面存在局限性.
- 新兴的替代方案在减少动物使用和提高生理学准确性方面显示出希望.
- 已经确定了纤维化和肝硬化中的关键生物标志物,组织病理学终点和分子参与者.
结论:
- 可靠的实验模型对于了解肝硬化症的复杂性和开发有效疗法至关重要.
- 新的体外和生物工程系统为更具预测性的临床前研究提供了有希望的途径.
- 未来的方向包括使用脱细胞化肝架和患者细胞进行个性化病理学,以改善临床结果预测.
相关概念视频
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
270
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
270
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
223
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
223
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
250
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
250
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
210
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
210
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
331
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
331
01:27Pharmacogenetics of Drug Metabolism: Overview
27
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
27